(Q38834921)

6 September 2017

Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line (English)

1 reference

6 September 2017

1 reference

1 reference

1 reference

1 reference

Jian-Huang Li

1

1 reference

6 September 2017

Ning Luo

2

1 reference

6 September 2017

Mei-Zuo Zhong

3

1 reference

6 September 2017

Zhi-Qiang Xiao

4

1 reference

6 September 2017

Jian-Xin Wang

5

1 reference

6 September 2017

Xiao-Yi Yao

6

1 reference

6 September 2017

Yun Peng

7

1 reference

6 September 2017

Jun Cao

8

1 reference

6 September 2017

16 September 2015

1 reference

6 September 2017

1 reference

6 September 2017

37

1 reference

6 September 2017

2

1 reference

6 September 2017

2387-2394

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-015-4017-7

6 September 2017

0 references

cites work

Targeted therapy for non-small-cell lung cancer: past, present and future

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Klotho sensitizes human lung cancer cell line to cisplatin via PI3k/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

SIRT1 and AMPK mediate hypoxia-induced resistance of non-small cell lung cancers to cisplatin and doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

microRNA regulation of cell viability and drug sensitivity in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

MicroRNA and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

MiR-196a is upregulated in gastric cancer and promotes cell proliferation by downregulating p27(kip1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

miR-196a regulates proliferation and osteogenic differentiation in mesenchymal stem cells derived from human adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Rnd3/RhoE Is down-regulated in hepatocellular carcinoma and controls cellular invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

miR-138 might reverse multidrug resistance of leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-015-4017-7

Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549/DDP cell apoptosis through HIF-1α and caspase-3 mechanisms

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26376998

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Role of tumor hypoxia in acquisition of resistance to microtubule-stabilizing drugs.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26376998

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13277-015-4017-7

1 reference

Dimensions Publication ID

6 September 2017

0 references

1 reference